MX385085B - Uso de beta-agonistas del receptor de la hormona tiroidea. - Google Patents
Uso de beta-agonistas del receptor de la hormona tiroidea.Info
- Publication number
- MX385085B MX385085B MX2018012900A MX2018012900A MX385085B MX 385085 B MX385085 B MX 385085B MX 2018012900 A MX2018012900 A MX 2018012900A MX 2018012900 A MX2018012900 A MX 2018012900A MX 385085 B MX385085 B MX 385085B
- Authority
- MX
- Mexico
- Prior art keywords
- agonists
- hormone receptor
- thyroid hormone
- receptor beta
- beta
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662326436P | 2016-04-22 | 2016-04-22 | |
| PCT/US2017/029120 WO2017185087A1 (en) | 2016-04-22 | 2017-04-24 | Use of thyroid beta-agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018012900A MX2018012900A (es) | 2019-07-01 |
| MX385085B true MX385085B (es) | 2025-03-14 |
Family
ID=60116400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018012900A MX385085B (es) | 2016-04-22 | 2017-04-24 | Uso de beta-agonistas del receptor de la hormona tiroidea. |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11351183B2 (enExample) |
| EP (1) | EP3445373B1 (enExample) |
| JP (1) | JP6931042B2 (enExample) |
| KR (1) | KR102407059B1 (enExample) |
| AU (1) | AU2017252126B2 (enExample) |
| BR (1) | BR112018071586A2 (enExample) |
| CA (1) | CA3021681C (enExample) |
| ES (1) | ES2992773T3 (enExample) |
| MX (1) | MX385085B (enExample) |
| WO (1) | WO2017185087A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2992773T3 (en) | 2016-04-22 | 2024-12-18 | Viking Therapeutics Inc | Use of thyroid beta-agonists |
| EP3768690B1 (en) * | 2018-03-22 | 2025-08-27 | Viking Therapeutics, Inc. | Crystalline forms and methods of producing crystalline forms of a compound |
| US12102646B2 (en) | 2018-12-05 | 2024-10-01 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis and inflammation |
| US11752161B2 (en) | 2020-03-27 | 2023-09-12 | Gannex Pharma Co., Ltd. | Pharmaceutical compositions, method of making and method of using thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040091455A1 (en) | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
| JP2007524656A (ja) | 2003-10-23 | 2007-08-30 | セルジーン・コーポレーション | 疼痛を治療、改変および管理するための選択的サイトカイン阻害薬を含む組成物ならびにその使用方法 |
| EP1689383B1 (en) | 2003-11-19 | 2012-10-31 | Metabasis Therapeutics, Inc. | Novel phosphorus-containing thyromimetics |
| NZ561148A (en) | 2004-12-08 | 2008-12-24 | Sirion Therapeutics Inc | Methods, assays and compositions for treating retinol-related diseases |
| CA2606498C (en) * | 2005-05-26 | 2016-08-09 | Metabasis Therapeutics, Inc. | Novel phosphinic acid-containing thyromimetics |
| EP1898926A2 (en) | 2005-05-26 | 2008-03-19 | Metabasis Therapeutics, Inc. | Thyromimetics for the treatment of fatty liver diseases |
| US20090042857A1 (en) | 2006-02-20 | 2009-02-12 | Masuo Yamaoka | Novel Pharmaceutical |
| US20110071208A1 (en) | 2009-06-05 | 2011-03-24 | Protiva Biotherapeutics, Inc. | Lipid encapsulated dicer-substrate interfering rna |
| WO2011038207A1 (en) * | 2009-09-25 | 2011-03-31 | Metabasis Therapeutics, Inc. | Phosphorus-containing thyroid hormone receptor agonists and methods of use |
| CN107201364A (zh) | 2011-06-21 | 2017-09-26 | 阿尔尼拉姆医药品有限公司 | 用于抑制载脂蛋白c‑iii（apoc3）基因表达的组合物与方法 |
| WO2014178892A1 (en) * | 2013-05-03 | 2014-11-06 | Scanlan Thomas S | Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy |
| WO2016134292A1 (en) | 2015-02-20 | 2016-08-25 | Oregon Health & Science University | Derivatives of sobetirome |
| RU2719245C2 (ru) | 2016-02-29 | 2020-04-17 | Филип Моррис Продактс С.А. | Тара и заготовка с шарнирной крышкой |
| ES2992773T3 (en) | 2016-04-22 | 2024-12-18 | Viking Therapeutics Inc | Use of thyroid beta-agonists |
| AU2017252122B2 (en) | 2016-04-22 | 2023-02-09 | Viking Therapeutics, Inc. | Use of Thyroid beta-Agonists |
| CA3024680A1 (en) | 2016-05-18 | 2017-11-23 | Oregon Health & Science University | Derivatives of sobetirome |
-
2017
- 2017-04-24 ES ES17786798T patent/ES2992773T3/es active Active
- 2017-04-24 WO PCT/US2017/029120 patent/WO2017185087A1/en not_active Ceased
- 2017-04-24 CA CA3021681A patent/CA3021681C/en active Active
- 2017-04-24 US US16/095,228 patent/US11351183B2/en active Active
- 2017-04-24 MX MX2018012900A patent/MX385085B/es unknown
- 2017-04-24 AU AU2017252126A patent/AU2017252126B2/en active Active
- 2017-04-24 EP EP17786798.3A patent/EP3445373B1/en active Active
- 2017-04-24 JP JP2019507069A patent/JP6931042B2/ja active Active
- 2017-04-24 KR KR1020187033713A patent/KR102407059B1/ko active Active
- 2017-04-24 BR BR112018071586-7A patent/BR112018071586A2/pt not_active Application Discontinuation
-
2022
- 2022-05-06 US US17/738,621 patent/US11951114B2/en active Active
-
2024
- 2024-03-05 US US18/595,919 patent/US12440502B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3021681C (en) | 2024-09-24 |
| EP3445373A4 (en) | 2019-12-18 |
| KR20190039027A (ko) | 2019-04-10 |
| US11351183B2 (en) | 2022-06-07 |
| US20190321379A1 (en) | 2019-10-24 |
| US11951114B2 (en) | 2024-04-09 |
| JP6931042B2 (ja) | 2021-09-01 |
| KR102407059B1 (ko) | 2022-06-10 |
| ES2992773T3 (en) | 2024-12-18 |
| WO2017185087A1 (en) | 2017-10-26 |
| US20220257618A1 (en) | 2022-08-18 |
| MX2018012900A (es) | 2019-07-01 |
| AU2017252126A1 (en) | 2018-11-08 |
| EP3445373B1 (en) | 2024-08-21 |
| BR112018071586A2 (pt) | 2019-02-12 |
| US12440502B2 (en) | 2025-10-14 |
| EP3445373A1 (en) | 2019-02-27 |
| US20250000880A1 (en) | 2025-01-02 |
| CA3021681A1 (en) | 2017-10-26 |
| AU2017252126B2 (en) | 2023-02-09 |
| JP2019515033A (ja) | 2019-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP17063327A (es) | Receptores de antígeno quiméricos antidll3 y métodos de uso | |
| MX386587B (es) | ANTICUERPOS ANTI-CD79b Y MÉTODOS DE USO. | |
| ECSP18094857A (es) | Agonista del receptor de glucocorticoides e inmunoconjugados del mismo | |
| CR20160500A (es) | Anticuerpos anti-ox40 y métodos de uso | |
| CL2017000590A1 (es) | Anticuerpos anti-cll-1 e inmunoconjugados | |
| EA201791117A1 (ru) | Частичные агонисты инсулинового рецептора | |
| EA201790545A1 (ru) | Антитела и иммуноконъюгаты против her2 | |
| CL2017001289A1 (es) | Compuestos bicíclicos fusionados, sus composiciones y su uso para el tratamiento de enfermedades relacionadas con la modulación del receptor x farnesoide (fxr). | |
| MX372675B (es) | Anticuerpos anti-jagged1 y metodos de uso. | |
| MX2017005920A (es) | Anticuerpos anti-tim3 y metodos de uso. | |
| EA201791029A1 (ru) | Антитела против интерлейкина-33 и их применение | |
| MX376026B (es) | Inmunoreceptores especificos de claudina-6 y epitopos de celulas t. | |
| LT3183268T (lt) | Anti-cd123 chimerinis antigeno receptorius (car), skirtas naudoti vėžio gydymui | |
| ES2796903T8 (es) | Procedimiento de uso de inmunoconjugados anti-CD79b | |
| BR112017009517A2 (pt) | receptores de antígeno quimérico anti-cldn e métodos de uso | |
| CO2017002159A2 (es) | Derivados de heterociclilo opcionalmente condensados de pirimidina útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias | |
| MX384989B (es) | Uso de un agonista del receptor x retinoide (rxr) en combinación con una hormona tiroidea para el tratamiento de esclerosis múltiple. | |
| CL2016002008A1 (es) | Proceso para la elaboración de derivados de pirimidin sulfamida. | |
| CL2018003045A1 (es) | Semaglutida en afecciones cardiovasculares. | |
| MX2018007818A (es) | Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso. | |
| MX385085B (es) | Uso de beta-agonistas del receptor de la hormona tiroidea. | |
| MX384037B (es) | Anticuerpos anti-bromodesoxiuridina(brdu) y metodos de uso. | |
| EA201792312A1 (ru) | Конструкции на основе калихеамицина и способы их применения | |
| EA201790373A1 (ru) | Способы получения модуляторов toll-подобных рецепторов | |
| MX2018012904A (es) | Uso de beta-agonistas del receptor de la hormona tiroidea. |